177 related articles for article (PubMed ID: 22137317)
1. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.
Zhang C; Ryu YK; Chen TZ; Hall CP; Webster DR; Kang MH
Leuk Res; 2012 Mar; 36(3):342-9. PubMed ID: 22137317
[TBL] [Abstract][Full Text] [Related]
2. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
3. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.
Kang MH; Kang YH; Szymanska B; Wilczynska-Kalak U; Sheard MA; Harned TM; Lock RB; Reynolds CP
Blood; 2007 Sep; 110(6):2057-66. PubMed ID: 17536015
[TBL] [Abstract][Full Text] [Related]
4. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
Gu L; Xie L; Zuo C; Ma Z; Zhang Y; Zhu Y; Gao J
BMC Cancer; 2015 Jul; 15():529. PubMed ID: 26189041
[TBL] [Abstract][Full Text] [Related]
9. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
11. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
12. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
13. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.
Gu L; Zhou C; Liu H; Gao J; Li Q; Mu D; Ma Z
J Exp Clin Cancer Res; 2010 Nov; 29(1):150. PubMed ID: 21083937
[TBL] [Abstract][Full Text] [Related]
15. Akt and autophagy cooperate to promote survival of drug-resistant glioma.
Fan QW; Cheng C; Hackett C; Feldman M; Houseman BT; Nicolaides T; Haas-Kogan D; James CD; Oakes SA; Debnath J; Shokat KM; Weiss WA
Sci Signal; 2010 Nov; 3(147):ra81. PubMed ID: 21062993
[TBL] [Abstract][Full Text] [Related]
16. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia.
Wong J; Welschinger R; Hewson J; Bradstock KF; Bendall LJ
Oncotarget; 2014 Nov; 5(21):10460-72. PubMed ID: 25361005
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase (PI3K) signalling regulates insulin-like-growth factor binding protein-2 (IGFBP-2) production in human adipocytes.
Wilhelm F; Kässner F; Schmid G; Kratzsch J; Laner A; Wabitsch M; Körner A; Kiess W; Garten A
Growth Horm IGF Res; 2015 Jun; 25(3):115-20. PubMed ID: 25900365
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy overcomes glucocorticoid resistance in lymphoid malignant cells.
Jiang L; Xu L; Xie J; Li S; Guan Y; Zhang Y; Hou Z; Guo T; Shu X; Wang C; Fan W; Si Y; Yang Y; Kang Z; Fang M; Liu Q
Cancer Biol Ther; 2015; 16(3):466-76. PubMed ID: 25778879
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Evangelisti C; Cappellini A; Oliveira M; Fragoso R; Barata JT; Bertaina A; Locatelli F; Simioni C; Neri LM; Chiarini F; Lonetti A; Buontempo F; Orsini E; Pession A; Manzoli L; Martelli AM; Evangelisti C
J Cell Physiol; 2018 Mar; 233(3):1796-1811. PubMed ID: 28777460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]